Results 81 to 90 of about 3,975 (165)

Use of triple therapy containing Bictegravir in HIV-infected patients naïve or previously treated with other combinations: experience in a Veneto centre

, 2023
openEsperienza dell'ospedale di Vicenza sull'impiego di triplice terapia contenente Bictegravir in soggetti con infezione da HIV naïve o già trattati con altre ...
DISSEGNA, SIMONE
core  

Doravirina, doravirina/lamivudina/ tenofovir disoproxil fumarat, dolutegravir/lamivudina i emtricitabina/tenofovir alafenamida, sol i combinat amb bictegravir, darunavir/cobicistat i rilpivirina: indicació avaluada; tractament del virus de la immunodeficiència humana de tipus 1 (VIH-1) en pacients naïfs [PDF]

, 2021
Virus de la inmunodeficiencia humana de tipo 1; Pacientes naífs; TratamientoVirus de la immunodeficiència humana de tipus 1; Pacients naïfs; TractamentType 1 human immunodeficiency virus; Naïve patients; TreatmentEn aquest informe s’avaluen els ...
Programa d'Harmonització Farmacoterapèutica
core  

Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis : a case report

, 2020
We report here the case of a 32-year-old male with recent diagnosis of HIV that, 45 days after starting a single tablet regimen co-formulated with bictegravir, emtricitabine and tenofovir alafenamide (BIC/FTC/TAF), experienced severe epigastric pain ...
Gervasoni C., Cattaneo D., Filice C., Riva A.   +3 more
core   +1 more source

Evaluation of Manufacturing Robustness for a Biodegradable Subcutaneous Implant Containing Bictegravir for HIV Prevention

, 2023
According to World Health Organization (WHO), the global impact of human immunodeficiency virus (HIV) infection remains a significant concern, necessitating the development of effective prevention strategies.
Chen, Yu-Chieh
core  

AI-driven discovery of the antiretroviral drug bictegravir and etravirine as potent inhibitors against monkeypox and related poxviruses

Monkeypox virus (MPXV) has caused the 2022-2023 global mpox outbreak and the concurrent outbreaks in Africa. Mpox disproportionately affects immunologically vulnerable populations such as people living with HIV (PLWH).
Wang, Yining
core   +2 more sources

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate Regimen and Its Effect on Liver Steatosis Assessed by Fibroscan

Viruses
Background: Antiretroviral therapy has transformed HIV infection from a fatal disease to a chronic and manageable condition, but increasing health issues beyond acquired immunodeficiency syndrome, such as metabolic, liver, and cardiovascular diseases ...
Marcello Trizzino, Roberta Gaudiano, Dalila Mimì Arena, Luca Pipitò, Claudia Gioè, Antonio Cascio   +5 more
doaj   +1 more source

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants

Retrovirology, 2018
Background Integrase strand transfer inhibitors (INSTIs) are the class of antiretroviral (ARV) drugs most recently approved by the FDA for the treatment of HIV-1 infections.
Steven J. Smith, Xue Zhi Zhao, Terrence R. Burke, Stephen H. Hughes   +3 more
doaj   +1 more source

HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir

, 2020
A potential drug-drug interaction exists between divalent and trivalent cations (Ca2+, Fe3+, Mg2+, Al3+, Zn2+) and HIV-1 integrase strand transfer inhibitors (INSTIs).
Patricia L. DeMarais, Blake E. Max, Alex E. Rock, Pamala T. Vergara-Rodriguez   +3 more
core   +1 more source

Antiretroviral drugs from multiple classes induce loss of excitatory synapses between hippocampal neurons in culture

Frontiers in Pharmacology
Introduction: Antiretroviral (ARV) drugs have improved prognoses for people living with HIV. However, HIV-associated neurocognitive disorders (HAND) persist despite undetectable viral loads. Some ARVs have been linked to neuropsychiatric effects that may
Hannah M. McMullan, Benjamin M. Gansemer, Stanley A. Thayer   +2 more
doaj   +1 more source

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

, 2018
BACKGROUND: Bictegravir, co-formulated with emtricitabine and tenofovir alafenamide, has shown good efficacy and tolerability, and similar bone, renal, and lipid profiles to dolutegravir, abacavir, and lamivudine, in treatment-naive adults with HIV-1 ...
Ruane, Peter, Custodio, Joseph, Stellbrink, Hans-Jürgen, Molina, Jean-Michel, Mills, Anthony, Ward, Douglas, López-Cortés, Luis, Brinson, Cynthia, Cheng, Andrew, Brar, Indira, Podzamczer, Daniel, Liu, Hui, Martin, Hal, Quirk, Erin, Andreatta, Kristen   +14 more
core   +1 more source